Join our daily newsletter At The Bell to receive exclusive market insights
- Bio-Gene Technology (BGT) has landed a new US patent to expand the protection of its insecticide products
- The patent relates to the company’s Flavocide product for the control of pesticide-resistant pests and will expire in July 2038
- Bio-Gene says this extends its current coverage for its insecticide and pest control products in an agricultural environment
- CEO Richard Jagger said with the US being such a large market for the company’s products, the patent strengthens Bio-Gene’s negotiation position for future deals
- Bio-Gene shares are up 2.5 per cent to 8.2 cents at 11:38 am AEDT
Bio-Gene Technology (BGT) has been granted a new US patent to expand the protection of its insecticide products.
The patent application is focused on the company’s Flavocide product for the control of pesticide-resistant pests, and it expires in July 2038.
BGT said the new patent would extend the coverage for the use of Flavesone in an agricultural environment and in protecting stored plant parts from infestation by pesticide-resistant pests.
“With the USA being such a large market for our technologies, patent protection creates significant value for us and our commercial partners and considerably strengthens our negotiation position for future commercial deals,” Mr Jagger said.
“We are continuing to develop commercial applications for our products supported by
a number of existing and pending patents relevant to target markets throughout the world.”
BGTs aims to develop and commercialise a broad portfolio that targets insect control and management solutions worldwide.
The ag-tech company uses platform technology based on a naturally-occurring class of chemicals known as Beta-triketones to kill or knock down insects.
Bio-Gene shares were up 2.5 per cent to 8.2 cents at 11:38 am AEDT.
